In this trial, we conducted a phase Ib trial to assess whether the WEE1 inhibitor AZD1775 could be safely combined with cisplatin chemotherapy pre-operatively (Group A) and with adjuvant concurrent chemoradiation post-operatively (Group B) without excessive acute and late toxicities in HNSCC patients undergoing curative surgery. Here, WEE1 is linked to head and neck squamous cell carcinoma.